Engineer Tricorn says that its full year results will be worse than expected due to poor trading conditions in the US and UK.
A trading statement relating to the six months to September 2019 admits that margins have come under pressure in the US and demand is weak in the UK.
US demand is as expected, but tariffs with China have raised costs and it has been difficult to negotiate price increases.
Second quarter trading in the UK was particularly poor and first half revenues will fall by 12%. That means that group revenues will be 7% lower at around £10.6m and there will be a more significant fall in profit.
If trading does not improve then full year revenues could be £21.5m, compared with a previous forecast of £23m and that equates to pre-tax profit of £500,000 instead of £1.2m.
The share price fell from 18p to 11.5p.
The interims will be published on 4 December.
© 2019 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Omega Diagnostics will lose money this year, but it is on course to become profitable in 2020-21 as sales of the VISITECT CD4 test.
House broker Shore Capital has slashed its pre-tax profit forecast for engineer Tricorn Group by two-thirds to £420,000.
Evgen Pharma has entered into an agreement with The University of Dundee for the use of SFX-01 in a clinical trial in non-alcoholic steatohepatitis and liver fibrosis, where there is no existing treatment.